{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:21:32Z","timestamp":1783117292617,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014599","name":"The Mark Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109453","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:13:58Z","timestamp":1779466438000},"page":"109453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy"],"prefix":"10.1016","volume":"217","author":[{"given":"Farhad","family":"Kosari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-9556","authenticated-orcid":false,"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Disselhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9484","authenticated-orcid":false,"given":"Kim","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet Schaefer","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2026.109453_b0005","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/nar\/gkz097","article-title":"An estimate of the total number of true human miRNAs","volume":"47","author":"Alles","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109453_b0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"Jansson","year":"2012","journal-title":"Mol. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109453_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169324","article-title":"The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer","volume":"23","author":"Kipkeeva","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109453_b0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12032-025-02782-6","article-title":"Advancing the potential of nanoparticles for cancer detection and precision therapeutics","volume":"42","author":"Kiani","year":"2025","journal-title":"Med. Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2026.109453_b0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"10419","key":"10.1016\/j.lungcan.2026.109453_b0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109453_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006035","article-title":"Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy","volume":"11","author":"Desai","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109453_b0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109453_b0045","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated with Immune Checkpoint Inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109453_b0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex Chromosomal Rearrangements in Mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109453_b0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2021.04.024","article-title":"Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment","volume":"152","author":"Disselhorst","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109453_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lungcan.2026.109453_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ncrna.2025.02.003","article-title":"PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy","volume":"12","author":"Gurau","year":"2025","journal-title":"Noncoding RNA Res"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109453_b0070","article-title":"The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: a Systematic Literature Review","volume":"3","author":"Mansfield","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109453_b0075","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109453_b0080","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109453_b0085","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.21037\/jtd.2018.08.59","article-title":"Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma","volume":"10","author":"Liu","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109453_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114860","article-title":"Recent progress in hyaluronic acid based nanoparticles for the anti-tumor application","volume":"254","author":"Wang","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.lungcan.2026.109453_b0095","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2105-15-224","article-title":"MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing","volume":"15","author":"Kalari","year":"2014","journal-title":"BMC Bioinf."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109453_b0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109453_b0105","doi-asserted-by":"crossref","first-page":"i596","DOI":"10.1093\/bioinformatics\/btz314","article-title":"Large-scale inference of competing endogenous RNA networks with sparse partial correlation","volume":"35","author":"List","year":"2019","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109453_b0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1261\/rna.2239606","article-title":"TarBase: a comprehensive database of experimentally supported animal microRNA targets","volume":"12","author":"Sethupathy","year":"2006","journal-title":"RNA"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109453_b0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12859-019-2861-y","article-title":"miRspongeR: an R\/Bioconductor package for the identification and analysis of miRNA sponge interaction networks and modules","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Bioinf."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109453_b0120","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-24-0853","article-title":"Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer","volume":"31","author":"Saberzadeh-Ardestani","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109453_b0125","article-title":"FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Genet."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109453_b0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2217\/imt-2020-0283","article-title":"Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer","volume":"13","author":"Jalalvand","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109453_b0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/beta-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"Mortezaee","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109453_b0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00262-024-03634-4","article-title":"circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis","volume":"73","author":"Liu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2026.109453_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112213","article-title":"A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery","volume":"143","author":"Shadbad","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109453_b0150","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1541-7786.MCR-18-0831","article-title":"miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1","volume":"17","author":"Ashizawa","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109453_b0155","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1111\/jcmm.16700","article-title":"LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF-beta pathway via miR-148a-3p\/AGO1 axis","volume":"25","author":"Wu","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.lungcan.2026.109453_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.877376","article-title":"Hsa_circ_0046523 Mediates an Immunosuppressive Tumor Microenvironment by Regulating MiR-148a-3p\/PD-L1 Axis in Pancreatic Cancer","volume":"12","author":"Fu","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109453_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010125","article-title":"Serum Extracellular Vesicle-Derived microRNAs as potential Biomarkers for Pleural Mesothelioma in a European prospective Study","volume":"15","author":"Casalone","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109453_b0170","article-title":"High expression of RRM2 mediated by non-coding RNAs correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma","volume":"9","author":"Mao","year":"2022","journal-title":"Front Med (lausanne)"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109453_b0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3724\/abbs.2023287","article-title":"lncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition by sponging miR-125a-5p and upregulating ANLN and RRM2","volume":"56","author":"Cao","year":"2024","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.lungcan.2026.109453_b0180","article-title":"Deciphering the Role of Shugoshin-like Protein 1 in Lung Adenocarcinoma: a Comprehensive Analysis and In Vitro Study","volume":"12","author":"Yuan","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109453_b0185","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4274\/balkanmedj.galenos.2022.2022-3-26","article-title":"Serum Expression Levels of Certain miRNAs in predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma","volume":"39","author":"Metintas","year":"2022","journal-title":"Balkan Med. J."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109453_b0190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1073\/pnas.1424217112","article-title":"In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA","volume":"112","author":"La Rocca","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:46:29Z","timestamp":1783115189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"alternative-id":["S0169500226005143"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109453","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109453"}}